CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced that its senior management team will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on the company’s Investors section of its website. Following the event, a replay will be available for 14 days. CRISPR Therapeutics focuses on developing gene-based medicines using CRISPR/Cas9 technology to address serious diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 11^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022, at 1:40 p.m. ET.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS^® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com 

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com 

FAQ

What date is CRISPR Therapeutics participating in the SVB Leerink Global Healthcare Conference?

CRISPR Therapeutics will participate in the SVB Leerink Global Healthcare Conference on February 16, 2022.

What time will the CRISPR Therapeutics event at the conference start?

The event will start at 1:40 p.m. ET on February 16, 2022.

Where can I watch the CRISPR Therapeutics conference presentation?

You can watch the presentation on the Investors section of CRISPR Therapeutics' website during the live webcast.

How long will the CRISPR Therapeutics conference replay be available?

The replay of the conference will be available for 14 days following the presentation.

What technology does CRISPR Therapeutics use for its gene-based medicines?

CRISPR Therapeutics uses the CRISPR/Cas9 technology for developing gene-based medicines.